BiotechTube

SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV Infection

Conditions

SARS-CoV Infection, Covid19

Trial Timeline

Dec 27, 2020 → Dec 15, 2023

NCT ID
NCT04611802

About SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)

SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination) is a phase 3 stage product being developed by Novavax for SARS-CoV Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04611802. Target conditions include SARS-CoV Infection, Covid19.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04611802Phase 3Completed

Competing Products

20 competing products in SARS-CoV Infection

See all competitors
ProductCompanyStageHype Score
CT-P59CelltrionPhase 1
33
CT-P63 + PlaceboCelltrionPhase 1
33
CT-P59 + CT-P59 + Placebo + CT-P59 + PlaceboCelltrionPhase 2/3
65
CT-P59 + PlaceboCelltrionPhase 1
33
Edoxaban Tablets + Colchicine TabletsDaiichi SankyoPhase 3
77
S-268019-b + PlaceboShionogiPhase 3
77
S-217622 + PlaceboShionogiPhase 3
77
S-217622 + PlaceboShionogiPhase 3
77
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
Nitric OxideGlenmark PharmaceuticalsPhase 3
77
Mesenchymal stem cell + PlaceboRohto PharmaceuticalPhase 2
52
EvusheldAstraZenecaPre-clinical
23
Biological: AZD3152 + Biological: PlaceboAstraZenecaPhase 2
52
AZD5156 (Parent study Sentinel Safety Cohort) + Placebo (Parent study Sentinel Safety Cohort) + EVUSHELD™ (Parent study Main Cohort) + AZD3152 (Parent study Main Cohort) + Placebo (Parent study Main Cohort) + AZD3152 (Sub-study) + AZD7442 - EVUSHELD™ (Sub-study) + AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152AstraZenecaPhase 2/3
65
EVUSHELDAstraZenecaPre-clinical
23
AZD1222AstraZenecaApproved
85
AZD3152 (Cohort 1) + Placebo (Cohort 1) + AZD3152 (Cohort 2) + Placebo (Cohort 2) + AZD3152 (Cohort 3) + Placebo (Cohort 3)AstraZenecaPhase 1
33
EVUSHELDAstraZenecaPre-clinical
23
AZD7442AstraZenecaPhase 1
33
EVUSHELDAstraZenecaPre-clinical
23

Other Products from Novavax

Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)Approved
80
protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineApproved
80
NVX-CoV2705 + PlaceboApproved
80
NVX-CoV2373 + BBIBP-CorV vaccinePhase 3
72
RSV-F Vaccine + Phosphate Buffer PlaceboPhase 3
72